Opinion on Oncology

Published within

« | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | ... | » »|

Type Product title / description Pub Price
Expert View
Expert View

A new phase in the breast cancer battle?

Published By Datamonitor
21 Sep 2001
CommentWire
CommentWire

Abbott Laboratories/Vysis: agreement for cancer tests

Published By Datamonitor
09 Apr 2001
CommentWire
CommentWire

Abbott: hope remains despite Xinlay setback

Abbott Laboratories has been dealt something of a blow after the FDA issued a 'not approvable' letter for Xinlay in metastatic hormone-refractory prostate cancer (HRPC). However, Abbott has said the rejection will not affect an ongoing late-stage trial in non-metastatic HRPC, suggesting that there could still be future hope for the drug.

Published By Datamonitor
18 Oct 2005
CommentWire
CommentWire

Abbott: positive results for prostate cancer drug

Published By Datamonitor
04 Jun 2001
CommentWire
CommentWire

Abbott: Xinlay unlikely to challenge Taxotere's dominance

Abbott's Xinlay has been granted fast track status by the FDA for the treatment of metastatic hormone-refractory prostate cancer. The treatment's favorable toxicity profile and oral formulation mean that, if approved, uptake should be strong. However, Aventis's Taxotere could become the gold standard and Abbott will need to provide solid survival data if Xinlay is to rival Taxotere's success.

Published By Datamonitor
12 Jul 2004
CommentWire
CommentWire

Abgenix/Amgen: colon cancer drug could challenge Erbitux

Abgenix and Amgen plan to submit an application to market colon cancer drug panitumumab by the end of 2005 after US regulators awarded the drug fast track status. With this indication already dominated by Genentech's Avastin and ImClone's Erbitux, panitumumab will need to demonstrate a survival advantage in phase III testing in order to establish itself in the colon cancer drug market.

Published By Datamonitor
03 Aug 2005
CommentWire
CommentWire

Abgenix: a new trial for promising cancer drug

Abgenix's drug could have a promising future. If the compound can improve upon the side effect profile of Roche/Genentech's benchmark monoclonal antibody Herceptin (trastuzumab), as well as gaining further indications, it is likely to become a key player within this field of anticancer treatments.

Published By Datamonitor
07 Jan 2002
CommentWire
CommentWire

Abraxis BioScience: Abraxane will face strong competition in Europe

Abraxane, a novel reformulation of paclitaxel, will be a welcome additional treatment option for metastatic breast cancer patients in Europe. Although uptake of the drug could be limited due to competition from well-established therapies, Abraxis could benefit from collaborating with a larger oncology player to effectively market Abraxane.

Published By Datamonitor
24 Jan 2008
CommentWire
CommentWire

Abraxis: clear regulatory pathway for Abraxane in lung cancer

Abraxis has reached an agreement with the FDA under the special protocol assessment process for a pivotal trial involving Abraxane. The Phase III non-small cell lung cancer trial will investigate this albumin-bound paclitaxel reformulation in the first-line setting. The agreement provides a clear pathway for horizontal expansion for Abraxane if the trial endpoints are achieved.

Published By Datamonitor
17 Oct 2007
Expert View
Expert View

Adjuvant therapy offers hope against deadly cancer

Non small cell lung cancer (NSCLC) is the most common form of lung cancer in the world, afflicting more than 330,000 new patients in the seven major pharmaceutical markets every year. However, according to a new report from Datamonitor, new trials have confirmed the effectiveness of adjuvant therapy, which is expected to rapidly become the standard therapy for NSCLC.

Published By Datamonitor
03 Dec 2004

« | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | ... | » »|

No help is available.